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Evaluation of cumulative prognostic scores based on the systemic
inflammatory response in patients with inoperable non-small-cell
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A score based on the combination of the systemic inflammatory response and albumin hazards ratio (HR) 1.70, 95% CI 1.23 – 2.35,
P¼0.001) was comparable in prognostic value to that based on stage and performance status (HR 1.48, 95% CI 1.12 – 1.95,
P¼0.006) in patients with inoperable non-small-cell lung cancer. The former is simple to measure and well standardised.
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Non-small-cell lung cancer is the most common cause of cancer
death in North America and Western Europe. Most patients
present with advanced inoperable disease and consequently the
prognosis of these patients is extremely poor. Conventionally, the
selection of patients for active or supportive treatment has been
based on clinicopathological criteria, including age, stage,
performance status, weight-loss or hypoalbuminaemia (Numico
et al, 2001). However, the assessment of both performance status
and the presence of weight loss may be subjective. For example,
significant differences in the assessment of performance status
have been reported between oncologists, nurses and patients,
oncologists being the most optimistic in their assessment and
patients the least (Ando et al, 2001).
Recent studies have shown that the presence and the magnitude
of a systemic inflammatory response, as evidenced by increased
circulating concentrations of C-reactive protein, is a prognostic
factor independent of age, stage, performance status, weight-loss
and hypoalbuminaemia in patients with advanced cancer including
non-small-cell lung cancer (NSCLC) (Martin et al, 1999; O’Gorman
et al, 2000; Mahmoud and Rivera, 2002; Scott et al, 2002).
The aim of the present study was to assess the value of
combining C-reactive protein and recognised prognostic factors as
stage, performance status and hypoalbuminaemia to form new
prognostic scores for patients with inoperable NSCLC.
MATERIALS AND METHODS
Study design
Patients presenting with inoperable NSCLC (stages III and IV) to a
single multidisciplinary oncology clinic in Glasgow Royal Infirm-
ary between January 1997 and October 2002 were included in the
study. Information was abstracted from the case notes by a
specially trained research nurse (LMF). Data for 1997–1999 were
collected retrospectively and that for 2000–2002 prospectively. All
patients had cytologically or histologically confirmed disease and
were staged on the basis of clinical findings, chest X-ray, and
where appropriate, bronchoscopy, liver ultrasound, isotope bone
scan and computerised tomography of the thorax, according to the
American Thoracic Society TNM classification (Mountain, 1991).
Clinical stage, tumour type and performance status (Eastern
Cooperative Oncology Group, ECOG) were recorded at the time of
diagnosis. A blood sample was also obtained for measurement of
haemoglobin, white cell count, albumin and C-reactive protein
concentrations. Patients were considered to have undergone active
treatment if they received chemotherapy (mainly cisplatin based)
and/or radical radiotherapy. Patients receiving palliative radio-
therapy and/or palliative care (symptom control) were considered
to have had supportive treatment.
The study was approved by the Research Ethics Committee of
Glasgow Royal Infirmary.
Methods
Blood parameters Routine laboratory measurements of haemo-
globin, white cell count, albumin and C-reactive protein concen-
tration were carried out. The coefficient of variation for these
methods, over the range of measurement, was less than 5% as
established by routine quality control procedures.
Statistics
Data are presented as median and range. Grouping of the variables
age, tumour type, performance status (ECOG), haemoglobin, white
cell count and albumin was carried out using standard thresholds
(Paesmans et al, 1997; Herndon et al, 1999). C-reactive protein
concentrations were also grouped (p10/410mgl
 l) as previously
described (O’Gorman et al, 2000). Prognostic scores were
constructed by assigning one point for each of the following Received 10 March 2003; revised 25 June 2003; accepted 8 July 2003
*Correspondence: Dr DC McMillan;
E-mail: d.c.mcmillan@clinmed.gla.ac.uk
British Journal of Cancer (2003) 89, 1028–1030
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
ycriteria: stage IV, ECOG 2–4, albumin o35gl
 l and C-reactive
protein 410mgl
 l. Cumulative scores were obtained by combin-
ing C-reactive protein with each of the other variables.
Univariate survival analysis was performed using the Kaplan–
Meier method. Multivariate survival analysis and calculation of
hazard ratios (HR) were performed using the Cox regression
analysis with prognostic scores as covariates. Deaths up to 31
January 2003 were included in the analysis. Analysis was
performed using SPSS software (SPSS Inc., Chicago, IL, USA).
RESULTS
The characteristics of patients with inoperable NSCLC (n¼161)
are shown in Table 1. The majority were male, over the age of 60
years, had stage IV disease and had good performance status.
Approximately, 20% had hypoalbuminaemia and 80% had an
elevated C-reactive protein concentration. One-third of patients
received active treatment (64% received cisplatin-based che-
motherapy); the remaining patients received supportive treatment.
In all, 118 (73%) of patients died during the follow-up period.
On univariate survival analysis, stage (Po0.05), tumour type
(Po0.01), performance status (Po0.001), white cell count
(Po0.01), albumin (Po0.001) and C-reactive protein (Po0.01)
were significant predictors of survival. On multivariate survival
analysis all these variables, with the exception of white cell count,
remained independent significant predictors of survival. There was
a significant correlation between C-reactive protein and albumin
concentrations (rs¼ 0.443, Po0.001).
On univariate analysis, the relationship between the prognostic
scores based on the combinations of C-reactive protein with stage,
performance status and albumin, respectively, and the median
survival is shown in Table 2. All these prognostic scores had HR in
the range 1.7–2.0 which was comparable with that for the score
based on the combination of stage and performance status.
On multivariate analysis, when the three scores based on the
combinations of the systemic inflammatory response and stage,
performance status and albumin were compared with the
combination of stage and performance status, only the score
based on the combination of the systemic inflammatory response
and albumin (HR 1.70, 95% CI 1.23–2.35, P¼0.001) and the score
based on stage and performance status (HR 1.48, 95% CI 1.12–
1.95, P¼0.006) retained independent significance.
DISCUSSION
In the present study, both the established indicators of the
presence of a systemic inflammatory response, white cell count
and C-reactive protein, were predictive of survival in patients with
inoperable NSCLC. This is consistent with previous studies, which
have shown that a raised white cell count (Paesmans et al, 1997)
Table 1 Clinical characteristics and survival in patients with inoperable
NSCLC: univariate survival analysis
Patients
161 (100%)
Survival (months)
Median (95% CI) P value
Age
o60years 37 (23) 10.3 (8.2–12.4)
X60years 124 (77) 8.2 (6.1–10.3) 0.593
Sex
Male 105 (65) 9.1 (6.6–11.6)
Female 56 (35) 8.9 (5.9–11.8) 0.810
Stage
III 57 (35) 12.0 (8.1–15.9)
IV 104 (65) 6.9 (4.0–9.9) 0.015
Type
Squamous 64 (40) 9.7 (5.9–13.5)
Adenocarcinoma 53 (33) 9.0 (2.6–15.3)
Other 44 (27) 3.9 (0.2–7.9) 0.003
Performance status (ECOG)
0–1 91 (57) 12.0 (8.7–15.4)
2–4 70 (43) 4.2 (1.6–6.7) o0.001
Haemoglobin
X12gl
 l 101 (63) 9.1 (6.3–11.9)
o12gl
 l 60 (37) 8.9 (6.4–11.3) 0.187
White cell count
p10 10
9l
 l 82 (51) 12.4 (7.9–16.9)
410 10
9l
 1 79 (49) 6.5 (2.9–10.0) 0.003
Albumin
X35gl
 l 126 (78) 10.1 (7.4–12.8)
o35gl
 l 35 (22) 3.7 (2.3–5.1) o0.001
C-reactive protein
p10mgl
 l 29 (18) 16.4 (11.0–21.7)
410mgl
 l 132 (82) 7.1 (4.9–9.3) 0.003
Treatment
Active 63 (39) 13.3 (10.4–16.2)
Palliative 98 (61) 4.7 (2.0–7.5) o0.001
Table 2 Cumulative prognostic scores and survival in patients with inoperable NSCLC (n¼161): univariate survival analysis
CRP/stage (n) CRP Stage Cumulative scores Survival (months) Hazard ratio (95%CI)
14 p10mgl
 l III 0 18.2 (14.5–21.9)
15 IV 1 10.4 (7.9–12.8)
43 410mgl
 l III 1 8.9 (5.5–12.3) 1.73 (1.23–2.33)
89 IV 2 6.1 (3.4–8.7) Po0.001
CRP/ECOG CRP ECOG
23 p10mgl
 l 0–1 0 17.9 (15.5–20.3)
6 2–4 1
68 410mgl
 l 0–1 1 9.0 (4.3–13.6) 1.79 (1.37–2.35)
64 2–4 2 4.2 (2.2–6.2) Po0.001
CRP/albumin CRP Albumin
27 p10mgl
 l X35gl
 1 0 17.0 (11.4–22.6)
2 o35gl
 1 1
99 410mgl
 l X35gl
 1 1 8.9 (6.3–11.4) 2.00 (1.47–2.70)
33 o35gl
 1 2 3.9 (0.8–7.1) Po0.001
Stage/ECOG Stage ECOG
40 III 0–1 0 16.1 (9.5–22.6)
17 2–4 1 9.7 (3.5–15.8)
51 IV 0–1 1 10.4 (5.8–14.9) 1.73 (1.33–2.24)
53 2–4 2 3.6 (1.7–5.6) Po0.001
CRP¼C-reactive protein; median survival (95% CI).
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prognostic value, independent of stage, in patients with inoperable
NSCLC.
When C-reactive protein concentrations were combined with
stage, performance status and albumin to form new prognostic
scores, these combined scores improved the prediction of survival
based on stage, performance status or albumin alone. Indeed, in
each of the cumulative scores, the presence of an elevated C-
reactive protein was associated with a halving of survival.
Furthermore, when these three combinations were compared to
the conventional combination of stage and performance status, the
combination of the systemic inflammatory response and albumin
and the conventional clinical combination stage and performance
status were found to have comparable prognostic value. To our
knowledge, this is the first study to present a cumulative
prognostic score based on C-reactive protein and albumin in
patients with advanced NSCLC.
In the present study, there was a significant difference in
survival between those receiving active treatment and those
receiving palliative care. However, this is not surprising since
those selected for active treatment tend to be the fitter patients.
Indeed, in the present study, 50% of patients with good
performance status (ECOG 1–2) and 14% of those with poor
performance status (ECOG 3–4) received active treatment.
Treatment was not included in the prognostic model since the
selection of patients for active treatment is based primarily on
performance status.
These results are consistent with the evidence that chronic
activation of the systemic inflammatory response is detrimental to
the outcome of patients with NSCLC, being associated with an
increase in weight loss (Staal van den Brekel et al, 1995; Scott et al,
1996) and fatigue (Scott et al, 2003), loss of lean tissue (McMillan
et al, 1998; Simons et al, 1999), decreased performance status and
survival (Martin et al, 1999; Scott et al, 2002).
The mechanism by which a systemic inflammatory response is
evoked in patients with NSCLC is not clear. One possibility is that
since many patients have coexisting pulmonary infection, the
resultant increase in white blood cells would lead to increased
proinflammatory cytokine release and a subsequent increase in
circulating C-reactive protein concentrations. However, in this
study, although the white cell count was significantly correlated
with C-reactive protein concentrations, the magnitude of the
relationship was small (r
2 less than 15%). This would suggest that
infection was not the main stimulus to the increased C-reactive
protein concentrations.
An alternative explanation would be that proinflammatory
cytokines are produced by the tumour. Indeed, there is evidence
that proinflammatory cytokines are produced locally by tumours
in patients with NSCLC (Arias-Diaz et al, 1994). In particular,
interleukin-6 is recognised as a primary mediator of increased
C-reactive protein concentrations in these patients (Yanagawa et al,
1995; Scott et al, 1996). However, whether interleukin-6 is
produced directly by lung cancer cells remains unclear.
In conclusion, the results of the present study suggest that a
cumulative score based on C-reactive protein and albumin may
have prognostic value similar to that provided by more conven-
tional measures. However, the cumulative score based on C-
reactive protein and albumin has the advantage that of being
simple to measure, routinely available and well standardised.
Further large-scale prospective studies are required to confirm
these findings and establish its value as a guide to the selection of
patients for treatment.
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